BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 14602867)

  • 1. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
    Carlin S; Akabani G; Zalutsky MR
    J Nucl Med; 2003 Nov; 44(11):1827-38. PubMed ID: 14602867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.
    Lundh C; Lindencrona U; Postgård P; Carlsson T; Nilsson M; Forssell-Aronsson E
    J Nucl Med; 2009 Jul; 50(7):1161-7. PubMed ID: 19525464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.
    Willhauck MJ; Sharif Samani BR; Klutz K; Cengic N; Wolf I; Mohr L; Geissler M; Senekowitsch-Schmidtke R; Göke B; Morris JC; Spitzweg C
    Gene Ther; 2008 Feb; 15(3):214-23. PubMed ID: 17989705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
    Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM
    Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.
    Carlin S; Mairs RJ; Welsh P; Zalutsky MR
    Nucl Med Biol; 2002 Oct; 29(7):729-39. PubMed ID: 12381453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
    Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
    Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
    Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
    Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose.
    Haberkorn U; Kinscherf R; Kissel M; Kübler W; Mahmut M; Sieger S; Eisenhut M; Peschke P; Altmann A
    Gene Ther; 2003 May; 10(9):774-80. PubMed ID: 12704416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter.
    Park SY; Kwak W; Thapa N; Jung MY; Nam JO; So IS; Kim SY; Yoo J; Lee J; Kim IS
    J Nucl Med; 2008 Sep; 49(9):1480-8. PubMed ID: 18703598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
    Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids.
    Mitrofanova E; Hagan C; Qi J; Seregina T; Link C
    Anticancer Res; 2003; 23(3B):2397-404. PubMed ID: 12894520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
    Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
    Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
    Scholz IV; Cengic N; Baker CH; Harrington KJ; Maletz K; Bergert ER; Vile R; Göke B; Morris JC; Spitzweg C
    Gene Ther; 2005 Feb; 12(3):272-80. PubMed ID: 15510175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
    Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
    J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
    Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
    Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy.
    Shen DH; Marsee DK; Schaap J; Yang W; Cho JY; Hinkle G; Nagaraja HN; Kloos RT; Barth RF; Jhiang SM
    Gene Ther; 2004 Jan; 11(2):161-9. PubMed ID: 14712300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two-and three-dimensional models.
    Carlin S; Cunningham SH; Boyd M; McCluskey AG; Mairs RJ
    Cancer Gene Ther; 2000 Dec; 7(12):1529-36. PubMed ID: 11228531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
    Mitrofanova E; Unfer R; Vahanian N; Link C
    Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
    Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
    J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
    Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
    Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.